BetterLife Pharma (BETRF) Return on Capital Employed (2016 - 2022)
BetterLife Pharma (BETRF) posted quarterly Return on Capital Employed of 251.93% for Q2 2022, down 90218.0% year-over-year from N/an in Q2 2021, and down 57.58% quarter-over-quarter from 593.94% in Q1 2022.
BetterLife Pharma (BETRF) Return on Capital Employed (2016 - 2022) Analysis & Trends
BetterLife Pharma's Return on Capital Employed history runs 7 years deep, the most recent figure standing at 251.93% for Q2 2022.
- In Q2 2022, Return on Capital Employed fell 90218.0% year-over-year to 251.93%; the TTM figure through Apr 2022 stood at 251.93% (down 90218.0% YoY), while the FY2026 annual figure was 24.89%, down 4403.0% from the prior year.
- Return on Capital Employed for Q2 2022 stood at 251.93%, down from 593.94% in the prior quarter.
- The five-year high for Return on Capital Employed was 4885.68% in Q3 2021, with the low at 4948.57% in Q4 2021.
- The 5-year median for Return on Capital Employed is 91.98% (2020), against an average of 210.07%.
- Peak annual rise in Return on Capital Employed reached 497766 bps in 2021, while the deepest fall reached 453169 bps in 2021.
- BetterLife Pharma's Return on Capital Employed stood at 118.66% in 2018, then decreased by 29 bps to 152.61% in 2019, then tumbled by 173 bps to 416.87% in 2020, then plunged by 1087 bps to 4948.57% in 2021, then soared by 105 bps to 251.93% in 2022.
- Business Quant data shows BETRF's Return on Capital Employed at 251.93% in Q2 2022, 593.94% in Q1 2022, and 4948.57% in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | BetterLife Pharma | 36.45 Mn | 36.42 Mn | - | 33.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2022 | 251.93% |
| Jan 31, 2022 | 593.94% |
| Oct 31, 2021 | -4,948.57% |
| Jul 31, 2021 | 4,885.68% |
| Apr 30, 2021 | 1,154.11% |
| Jan 31, 2021 | -3,393.94% |
| Oct 31, 2020 | -416.87% |
| Jul 31, 2020 | -91.98% |
| Apr 30, 2020 | -73.84% |
| Apr 30, 2019 | -152.61% |
| Oct 31, 2018 | -118.66% |
| Jul 31, 2017 | 161.25% |
| Apr 30, 2017 | 175.15% |
| Jan 31, 2017 | 422.33% |
| Oct 31, 2016 | 946.39% |
| Jul 31, 2016 | 1,649.23% |
| Apr 30, 2016 | 2,585.62% |
| Jan 31, 2016 | 3,406.96% |